1 FDA Perspective on Global Evaluation of Facial Acne Brenda Carr, M.D. Medical Officer Division of Dermatologic and Dental Drug Products FDA.

Slides:



Advertisements
Similar presentations
Table 1 - The scale of Hellegren and Vincent
Advertisements

Dr Stephen Chadwick GPsWI
Bronchoprovocation test Presented by: Ashraf Abbas ELMaraghy,MD. Lecturer of Chest Diseases, Ain Shams University.
Eugenie Coakley, Susan Grantham, Alec McKinney, Natalie Truesdell, Melina Ward May 4, 2012.
Case 30 Clinical information supplied  25 year old male patient with Crohn’s disease for 4 years.  Six week history of oral ulceration with cobblestoning.
ACNE Definition Inflammation of sebaceous follicles Follicle
DYNAMIC GAIT INDEX SEYED KAZEM MALAKOUTI, MD GERIATRIC MEDICINE DEPARTMENT IRAN UNIVERSITY OF MEDICAL SCIENCES Seyed Kazem Malakouti, MD.
Acne Vulgaris between Der. Pts in Palestine By Dr. Hisham Arda, M.D. Ph.D., Associate Prof. AN-Najah Univ. Nablus-Palestine.
Acne Treatment and Therapeutic Strategies
Acne Treatment and Therapeutic Strategies
Physical Examination of the Skin, Hair, and Nails.
How to use Clinical Evidence to inform clinical decision making A case presentation using the CE review on acne.
Rosacea and acne Aaron, Tyra, and Cariane.
Acne (Acne vulgaris) By Alex Edmonds. What is the disease? Acne vulgaris is a disease that is when you get pimples on your body.
Acne - A physical change in the skin caused by a disease process in the sebaceous follicle - Acne is the term for plugged pores (blackheads and whiteheads),
Clinically proven ingredients Economical price
 Question: Take a history from May Ling 15 years, examine her face,outline the most likely diagnosis and a management plan.
Skin Disorders of Diabetes Mellitus Pongsakorn Thitachote, MD.
MEASURES of CORRELATION. CORRELATION basically the test of measurement. Means that two variables tend to vary together The presence of one indicates the.
Alan Breier, M.D. Leader, Zyprexa Product Team Lilly Research Fellow Professor of Psychiatry, Indiana University School of Medicine Adjunct Associate of.
What’s new?. Acne is a common chronic skin condition which has a significantly negative psychological impact that can be directly improved with treatment.
Acne Vulgaris: Treatment with Azithromycin Kouzeva V, Hitova M, Dancheva A, Kaliasheva P City Center for Dermatovenerology, Sofia Bulgaria.
Acne Dr. Jerald E. Hurdle Kennebec Medical Consultants.
1 Mohamed Alosh, Ph.D. Kathleen Fritsch, Ph.D. Shiowjen Lee, Ph.D. DBIII, OB, CDER, FDA Efficacy Evaluation in Acne Clinical Trials.
Seborrheic Keratosis.
1 Markham C. Luke, M.D., Ph.D. Dermatology Clinical Team Leader DDDDP, ODE V, CDER, FDA Combination Topical Products for the Treatment of Acne Vulgaris.
Acne. Dr.Ahmed Abdul-Aziz Ahmed Assistant Clinical Professor Dermatology&Venerology. F.I.B.M.S.
Objectives What is acne? Pathogenesis. Acne lesion. Classification. Clinical variant of acne. What makes acne worse? Differential Diagnosis. Diagnosis.
Safety, Efficacy and Duration of Effect of RT002, a Botulinum Toxin Type A for Injection, to Treat Glabellar Lines: The Phase 2 BELMONT Study Authors:
Benefits Of Microdermabrasion – Remove Signs Of Aging HARLEY STREET COSMETIC CLINIC HARLEY STREET C O S M E T I C C L I N I C.
Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Adapalene Gel, 0.1%, as Maintenance Therapy for Acne.
Acne Vulgaris Prepared by: Dr. Murtadha Hashim Raheem MBChB;FICMS بورد ( دكتوراه ) اختصاص الامراض الجلديةوالتناسلية
M. Ansari COMPOUNDING FOR DERMATOLOGY PATIENTS. A CNE  Acne vulgaris is characterized by comedones and otherlesions, including scars and occurs throughout.
1 Clinical Studies Section of Labeling Joseph Porres, M.D., Ph.D. Medical Officer Division of Dermatologic and Dental Drug Products FDA.
Integumentary System Diseases and Abnormal Conditions
‘MIACARE’ Acne Patch BENQ.
Wrinkle Severity Rating Scale (WSRS) Training Slides
DISORDERS OF SEBACEOUS AND APOCRİNE GLANDS
Patient Focused Drug Development An FDA Perspective
Accurate wide field machine assessment of Acne and Rosacea
ACNE VULGARIS -Nisarg Kothari.
Assessing Psoriasis in the Clinic: PGA and BSA
Acne Vulgaris TSMU.
Acne vulgaris moderate. A
FDA Perspective on Cardiovascular Device Development
Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
A randomized, controlled trial of a low-dose contraceptive containing 20 μg of ethinyl estradiol and 100 μg of levonorgestrel for acne treatment  Diane.
Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Measuring Social Life: How Many? How Much? What Type?
Regulatory perspective
DISORDERS OF SEBACEOUS AND APOCRİNE GLANDS
Alopecia Areata Slide #32, "0232-Alopecia areata" from Set #2
Topical ALA-Photodynamic Therapy for the Treatment of Acne Vulgaris
Herpes Zoster (Shingles) and Postherpetic Neuralgia
A comparison of wound healing between a skin protectant ointment and a medical device topical emulsion after laser resurfacing of the perioral area  Deborah.
A randomized, controlled trial of a low-dose contraceptive containing 20 μg of ethinyl estradiol and 100 μg of levonorgestrel for acne treatment  Diane.
Visible flexural dermatitis – test photographs
The Adolescent With a Major Illness
A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies  Linda.
Acne Allie Shaw.
The Acne Landscape Is Evolving
Insert title (include diagnosis)
Postprocedural wound-healing efficacy following removal of dermatosis papulosa nigra lesions in an African American population: A comparison of a skin.
Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle.
Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne  Jerry Tan, MD, Diane Thiboutot, MD, Georg Popp,
Adapalene gel 0.3% for the treatment of acne vulgaris: A multicenter, randomized, double-blind, controlled, phase III trial  Diane Thiboutot, MD, David.
Presentation transcript:

1 FDA Perspective on Global Evaluation of Facial Acne Brenda Carr, M.D. Medical Officer Division of Dermatologic and Dental Drug Products FDA

2 §Challenges to scale design §Benefits of a common scale §Attributes of a scale §Examples of scales Outline

3 Challenges to Scale Design §pleomorphic nature of acne §variability in lesions §variability in natural course §what to assess

4 Benefits of a Standard Scale §Objective basis for treatment assessment §Assessment of disease status in clinical trials §Interpretation of trial results

5 Attributes of a Scale §A limited number of levels §Levels which are sufficiently described §Levels which indicate the “clear” (no acne) and “almost clear” state §Static measures to reflect a point in time §A high degree of correlation with lesion counts

6 Examples of Scales

7 Example #1 (Leed’s) §Grade 0 (no acne) to Grade 10 (most severe acne) §Grades 0 to 2: subdivided by 0.25 increments; 9 grades §Grades 2 to 10: subdivided by 0.50 increments; 17 grades

8 Example #2 (Cook’s) Grade 0: Need not be perfect; 3 small comedones and/or small papules if they are scattered Grade 2: Very few pustules or perhaps 3 dozen papules and/or comedones; no big or prominent lesions; lesions are hardly visible form 2.5 m away Grade 4: Between 2 and 6; red lesions and inflammation to a significant degree; worthy of treatment Grade 6: Loaded with comedones; no inflammation; or inflammatory lesions; must have numerous pustules; lesions are easily recognized at 2.5 m; some pustules may be quite large, 1 to 2 cm Grade 8: Conglobata, sinus, or cystic type acne; or a highly inflammatory acne covering most of the face; yellow pustules extend to neck and chin

9 Example #3 0 = worse 1 = no change 2 = slight improvement 3 = moderate improvement 4 = excellent improvement

10 Example #4 0 (None)= occasional comedones, but no evidence of acne requiring treatment 1 (Minimal) = non-inflammatory lesions predominate, several comedones and small papules/pustules, no inflamed nodulo-cystic lesions 2 (Mild) = non-inflammatory lesions predominate, multiple inflammatory lesions several to many comedones and small papules/pustules, perhaps 1 small evolving or involuting nodulo- cystic lesion 3 (Moderate) = inflammatory lesions are more apparent, many small papules/pustules, perhaps a few inflamed nodulo-cystic lesions 4 (Severe) = highly inflammatory lesions predominate, variable number of comedones several to many papules/pustules, several to many inflamed nodulo-cystic lesions

11 Example #5 0 (Normal)= clear skin with no evidence of acne vulgaris 1 (Almost clear) = a few to several (up to 15) non-inflammatory lesions (comedones) are present; a few (up to 7) inflammatory (papules/pustules) may be present 2 (Minimal to Mild) = several to many (>15) non-inflammatory lesions (comedones) are present; a few to several (>7) papules/pustules are present; no nodulo-cystic lesions 3 (Moderate) = many (>20) non-inflammatory and inflammatory (>20) lesions are present, there may or may not be 1 small nodulo-cystic lesion 4 (Severe) = High degree of inflammatory disease; papules/pustules are a predominant feature, variable number of comedones may be present; there may or may not be a few nodulo-cystic lesions

12 Example #6 0 = Normal, clear skin with no evidence of acne vulgaris 1 = Skin is almost clear: rare non-inflammatory lesions present, with rare non-inflamed papules (papules must be resolving and may be hyperpigmented, though not pink-red) 2 = Some non-inflammatory lesions are present, with few inflammatory lesions (papules/pustules only; no nodulo-cystic lesions) 3 = Non-inflammatory lesions predominate, with multiple inflammatory lesions evident: several to many comedones and papules/pustules, and there may or may not be one small nodulo-cystic lesion 4 = Inflammatory lesions are more apparent: many comedones and papules/pustules, there may or may not be a few nodulo-cystic lesions 5 = Highly inflammatory lesions predominate: variable number of comedones, many papules/pustules nodulo-cystic lesions